Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.20.4
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Income Statement [Abstract]    
Revenue $ 512,500
Operating costs and expenses:    
Inventor royalties, contingent legal fees, litigation and licensing expenses 385,002
Research and development expenses (including non-cash share-based compensation expenses of $290,207 and $397,523, respectively) 827,651 1,490,588
General and administrative expenses (including non-cash share-based compensation expenses of $695,892 and $623,811, respectively) 1,532,978 1,139,281
Total operating costs and expenses 2,745,631 2,629,869
Loss from operations (2,233,131) (2,629,869)
Interest income 754 13,294
Net loss (2,232,377) (2,616,575)
Less: Net loss attributable to noncontrolling interest (24,086) (24,032)
Net loss attributable to common shareholders $ (2,208,291) $ (2,592,543)
Net loss per common share attributable to common shareholders: Basic and diluted $ (0.09) $ (0.13)
Weighted average common shares outstanding: Basic and diluted 25,164,565 20,703,882